Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.62 |
| ▸ | CES1 | P23141 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | OGG1 | O15527 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3757531 | 0.80 | CES2 (0.65) | CES2CES1KMT2AMEN1LMNA | |
| SCHEMBL2440560 | 0.80 | CA1 (0.61) | KMT2AMEN1MAPTMAPK1RAB9A | |
| SCHEMBL2601260 | 0.80 | CA1 (0.61) | CES2CES1LMNAMAPTHTT | |
| SCHEMBL4587615 | 0.80 | CA1 (0.56) | CES2CES1KMT2ACA1CA2 | |
| SCHEMBL28450705 | 0.80 | MAPT (0.52) | CES2CES1KMT2AMEN1LMNA | |
| SCHEMBL13756423 | 0.79 | KMT2A (0.48) | CES2CES1KMT2AMEN1LMNA | |
| SCHEMBL536908 | 0.79 | MEN1 (0.48) | CES2CES1KMT2AMEN1LMNA | |
| SCHEMBL14712038 | 0.79 | CES2 (0.47) | CES2CES1KMT2AMEN1LMNA | |
| SCHEMBL836180 | 0.78 | CES2 (0.62) | CES2CES1KMT2AMEN1LMNA | |
| SCHEMBL12558164 | 0.78 | MAPK13 (0.45) | CES2CES1KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070874-A1 | BENZOYLFORMIC ACID AMIDE DERIVATIVE | KJ CHEMICALS CORPORATION (JP) | 2026-03-12 | — | — | US | disclosed |
| EP-4610249-A1 | BENZOYLFORMIC ACID AMIDE DERIVATIVE | KJ Chemicals Corporation (JP) | 2025-09-03 | — | — | EP | disclosed |
| WO-2024210074-A1 | BENZOYLFORMIC ACID AMIDE DERIVATIVE | ＫＪケミカルズ株式会社 | 2024-10-10 | — | — | WO | disclosed |
| CN-111116561-B | Compound containing condensed ring structure, application thereof and organic electroluminescent device | 北京绿人科技有限责任公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-111116561-A | Compound containing condensed ring structure, application thereof and organic electroluminescent device | 北京绿人科技有限责任公司 | 2020-05-08 | — | — | CN | disclosed |
| EP-0975584-B1 | SYNTHESIS AND USE OF ALPHA-KETOAMIDE DERIVATIVES AND ARRAYS | ARQULE INC (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6452050-B1 | MONOACYLATION OF SUCH AS 4-AMINOBENZYLAMINE WITH METHYL-2-(2-BENZOTHIENYL)-2-OXOETHANOATE TO PRODUCE POTENTIAL INHIBITORS OF PROTEOLYTIC ENZYMES, PARTICULARLY CYSTEINE PROTEASES | ARQULE, INC. | 2002-09-17 | — | — | US | disclosed |
| US-6143931-A | USEFUL IN DEVELOPING PHARMACEUTIC AGENTS FOR THE TREATMENT OF DISEASES (E.G., CHAGAS' DISEASE) | ARQULE, INC. (US) | 2000-11-07 | — | — | US | disclosed |
| WO-2000053313-A2 | LANTHANIDE CATALYSTS FOR SYNTHESIS OF COMPOUNDS AND COMBINATORIAL LIBRARIES | ARQULE, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| WO-1998046551-A9 | SYNTHESIS AND USE OF BIASED ARRAYS | — | 1999-03-18 | — | — | WO | disclosed |
| WO-1998046551-A1 | SYNTHESIS AND USE OF BIASED ARRAYS | ARQULE, INC. (US) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070874-A1 | BENZOYLFORMIC ACID AMIDE DERIVATIVE | CRYAA, BCAT1, BRCA1 | CES2 1111/4885CES1 945/4885KMT2A 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.